An Innovative Biomarker Driven Anticancer Antibody
Bessor Pharma

• Develops promising therapeutic assets from universities
• Deliver proof of concept, clinical ready packages for license or sale to pharma
• Utilize a fully integrated drug development/business network; top R and D team
• Focus on immuno-inflammation, immuno-oncology
Renalase as a novel cancer target

• Elevated expression in cancer and increased levels correlate with poor survival
  – Melanoma, pancreatic, bladder, NSCLC

• Overexpressed in animal models

• Released by tumor-associated macrophages

• Receptor activation promotes cytoprotection; increases cell survival in cancer.
Renalase deletion blunts lung tumor growth in mouse metastatic melanoma model

Wild type mouse with normal renalase levels

Renalase knock-out mouse; no renalase
Anti-Renalase antibody active in checkpoint inhibitor resistant mouse melanoma model
Anti-renalase antibody development progress

• Therapeutic antibody development
  • In vitro, and in vivo activity in melanoma and pancreatic cancer
  • Studies in other hard to treat cancers underway
  • Active in checkpoint inhibitor resistant melanoma models
  • Humanization under way

• Renalase assay being developed with potential as a biomarker

• Seeking partners to accelerate development
Uniquely translating university assets to innovative products